/ATXI
ATXI Stock - Avenue Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.65+0.05%
+$0.00 (+0.05%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1740.8%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATXI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.65 – $0.66
TARGET (TP)$12.00
STOP LOSS$0.60
RISK/REWARD1:218.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.33
52W High$2.23
52W Low$0.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-11,283,000 | $-14,540,000 | $-8,043,000 | $-3,738,000 | $-5,213,000 |
| Net Income | $-11,652,000 | $-10,377,000 | $-3,552,000 | $-3,731,000 | $-5,151,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.90 | $-73.60 | $-121.91 | $-3.29 | $-4.65 |
Company Overview
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATXIBeat Rate
46%
Last 13 quarters
Avg Surprise
+407.2%
EPS vs Estimate
Beats / Misses
6/7
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
+42210.0%
$42.11vs$-0.10
Q2 24
-71.1%
$-15.40vs$-9.00
Q3 24
-512.4%
$-6.43vs$-1.05
Q4 24
-104.3%
$-1.92vs$-0.94
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.21 | — | — |
Q3 2025 | Aug 14, 2025 | — | $0.11 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.62 | — | — |
Q1 2025 | Mar 31, 2025 | — | $1.48 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.94 | $-1.92 | -104.3% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-1.05 | $-6.43 | -512.4% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-9.00 | $-15.40 | -71.1% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.10 | $42.11 | +42210.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.26 | $4.51 | +1834.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.29 | $-39.10 | -13382.8% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.13 | $-103.01 | -79138.5% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.15 | $92.48 | +61753.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-45.00 | $-33.83 | +24.8% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-45.00 | $-33.82 | +24.8% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-45.00 | $-2.05 | +95.4% | ✓ BEAT |
Q1 2022 | Mar 25, 2022 | $-0.60 | $-0.75 | -25.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $-56.36 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-67.64 | — | — |
Q2 2021 | May 17, 2021 | $-0.90 | $-67.64 | -7415.6% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ATXI
What is ATXI's current stock price?
Avenue Therapeutics, Inc. (ATXI) is currently trading at $0.65 per share. The stock has moved +0.05% today.
What is the analyst price target for ATXI?
The average analyst price target for ATXI is $12.00, based on 1 analyst.
What sector is Avenue Therapeutics, Inc. in?
Avenue Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ATXI's market cap?
Avenue Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ATXI pay dividends?
No, Avenue Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
CARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
NCEL
NewcelX Ltd.
$2.60
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to ATXI for comparison